Olaparib in treatment‐refractory isocitrate dehydrogenase 1 (IDH1)– and IDH2‐mutant cholangiocarcinoma: Safety and antitumor activity from the phase 2 National Cancer Institute 10129 trial

Documenti analoghi

• Safety and efficacy of isocitrate dehydrogenase‐1 inhibitor ivosidenib in patients with cholangiocarcinoma
  di: Lindsay Wong, et al.
  Pubblicazione: (2026)
• Propensity Score‐Matched Comparison of Robotic and Laparoscopic Pancreaticoduodenectomy
  di: Bor‐Shiuan Shyr, et al.
  Pubblicazione: (2025)
• Impact of Obesity on Perioperative Outcomes in Robotic Pancreaticoduodenectomy: A Propensity Score‐Matched Study
  di: Bor‐Uei Shyr, et al.
  Pubblicazione: (2024)
• Interactions Between Carbon Fibre and Thermoplastics
  di: T. Shyr, et al.
  Pubblicazione: (1995)
• A Unified Framework for Statistical Inference and Power Analysis of Single and Comparative Fβ Scores
  di: Chih‐Yuan Hsu, et al.
  Pubblicazione: (2026)